Beckman, Recognizing Inverness' Bid for Biosite, Extends Own Offer Deadline | GenomeWeb
NEW YORK (GenomeWeb News) — Beckman Coulter today said it has extended its offer to buy Biosite to May 2, which the day that a counteroffer by Inverness Medical Innovations runs out.
 
Late last week, Biosite told Beckman Coulter that it “currently intends” to accept a rival offer from Inverness, which proposes to buy the company for $90 a share. Beckman’s original offer, made in March, was for $85 a share.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.